Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E, Rea CG, Capri G, Bianchi GV, de Braud F. Vernieri C, et al. Among authors: bianchi gv. Breast Cancer Res. 2020 Apr 6;22(1):33. doi: 10.1186/s13058-020-01271-0. Breast Cancer Res. 2020. PMID: 32252811 Free PMC article. Review.
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.
Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L, Mariani G, Bianchi GV, Capri G, de Braud F. Vernieri C, et al. Among authors: bianchi gv. Crit Rev Oncol Hematol. 2019 Jul;139:53-66. doi: 10.1016/j.critrevonc.2019.05.001. Epub 2019 May 3. Crit Rev Oncol Hematol. 2019. PMID: 31112882 Review.
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
Vernieri C, Prisciandaro M, Nichetti F, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, Manglaviti S, Brambilla M, Re B, Belfiore A, Pruneri G, Celio L, Mariani G, Bianchi GV, Rivoltini L, Capri G, de Braud F. Vernieri C, et al. Among authors: bianchi gv. Cancers (Basel). 2020 Mar 6;12(3):617. doi: 10.3390/cancers12030617. Cancers (Basel). 2020. PMID: 32155941 Free PMC article.
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
Vernieri C, Prisciandaro M, Milano M, Cona MS, Maggi C, Brambilla M, Mennitto A, Fabbroni C, Farè E, Cresta S, Celio L, Mariani G, Bianchi G, Capri G, de Braud F. Vernieri C, et al. Clin Breast Cancer. 2019 Apr;19(2):e306-e318. doi: 10.1016/j.clbc.2018.12.004. Epub 2018 Dec 12. Clin Breast Cancer. 2019. PMID: 30635175
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Lobefaro R, Zattarin E, Nichetti F, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, Beninato T, Mazzeo L, Rea CG, Mariani G, de Braud F, Bianchi GV, Vernieri C, Capri G. Lobefaro R, et al. Among authors: bianchi gv. Ther Adv Med Oncol. 2020 Dec 7;12:1758835920970081. doi: 10.1177/1758835920970081. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33335565 Free PMC article.
78 results